Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 373-384

  Liu, Min ^a,b   Matsumura, Noriomi ^a   Mandai, Masaki ^a   Li, Kui ^a   Yagi, Haruhiko ^a   Baba, Tsukasa ^a   Suzuki, Ayako ^a   Hamanishi, Junzo ^a   Fukuhara, Ken ^a   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; CD1a; CD57; CD8; Clustering; Cyclooxygenase; Ovarian

Indexed keywords

CD57 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; T6 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD1; ANTIGENS, CD57; CD8-POSITIVE T-LYMPHOCYTES; CLUSTER ANALYSIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; T-LYMPHOCYTE SUBSETS;

EID: 61349197486     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.187     Document Type: Article

References (54)

1. Boente MP, Schilder R, Ozols RF. Gynecologic cancers. Cancer Chemother Biol Response Modif 1997;17:536-561.
2. Petrulio CA, Kim-Schulze S, Kaufman HL. The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther 2006;6:671-684.
3. McDermott RS, Beuvon F, Pauly M, et al. Tumor antigens and antigen-presenting capacity in breast cancer. Pathobiology 2002;70:324-332.
4. Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-2328.
5. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000;88:577-583.
6. Allory Y, Bazille C, Vieillefond A, et al. Profiling and classification tree applied to renal epithelial tumours. Histopathology 2008;52:158-166.
7. Gamal G, Sano T, Sakurai S, et al. Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis. Pathol Int 2007;57:765-774.
8. Alkushi A, Clarke BA, Akbari M, et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007;20:1156-1165.
9. Papay J, Krenacs T, Moldvay J, et al. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach. Appl Immunohistochem Mol Morphol 2007;15:19-30.
10. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
11. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-146.
12. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-1536.
13. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609-1620.
14. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
15. Rask K, Zhu Y, Wang W, et al. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 2006;5:62.
16. Li S, Miner K, Fannin R, et al. Cyclooxygenase-1 and -2 in normal and malignant human ovarian epithelium. Gynecol Oncol 2004;92:622-627.
17. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-370.
18. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006;6:613-625.
19. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-3365.
20. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384.
21. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
22. Katou F, Ohtani H, Watanabe Y, et al. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer. Cancer Res 2007;67:11195-11201.
23. Tomsova M, Melichar B, Sedlakova I, et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415-420.
24. Barth TF, Barth CA, Kestler HA, et al. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma. J Pathol 2007;211:305-313.
25. Prasad ML, Barbacioru CC, Rawal YB, et al. Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol 2008;21:105-114.
26. Coventry BJ, Lee PL, Gibbs D, et al. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 2002;86:546-551.
27. Coventry BJ, Morton J. CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer 2003;89:533-538.
28. Goldman SA, Baker E, Weyant RJ, et al. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998;124:641-646.
29. Iwamoto M, Shinohara H, Miyamoto A, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003;104:92-97.
30. Reichert TE, Scheuer C, Day R, et al. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001;91:2136-2147.
31. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
32. Chiba T, Ohtani H, Mizoi T, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-1717.
33. Kondratiev S, Sabo E, Yakirevich E, et al. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004;10:4450-4456.
34. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-361.
35. Prall F, Duhrkop T, Weirich V, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35:808-816.
36. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543.
37. Seo SS, Song YS, Kang DH, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 2004;92:927-935.
38. Munkarah A, Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 2005;17:49-53.
39. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-911.
40. Rubio MT, Means TK, Chakraverty R, et al. Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 Tcell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. Int Immunol 2005;17:1561-1572.
41. Bang S, Kim HS, Choo YS, et al. Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. Pancreas 2006;32:29-36.
42. Chell S, Kaidi A, Williams AC, et al. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006;1766:104-119.
43. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007;58:239-252.
44. Kojima F, Kato S, Kawai S. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol 2005;19:255-261.
45. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003;111:727-735.
46. Chen TH, Fukuhara K, Mandai M, et al. Increased cyclooxygenase-2 expression is correlated with suppressed antitumor immunity in cervical adenocarcinomas. Int J Gynecol Cancer 2006;16:772-779.
47. Ferrandina G, Lauriola L, Zannoni GF, et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002;87:1145-1152.
48. Ohno Y, Ohno S, Suzuki N, et al. Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer 2005;114:696-701.
49. Iwamoto A, Ikeguchi M, Matsumoto S, et al. Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori 2006;92:130-133.
50. Hilmy M, Campbell R, Bartlett JM, et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2006;95:1234-1238.
51. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-7852.
52. Haas AR, Sun J, Vachani A, et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006;12:214-222.
53. Tanaka T, Delong PA, Amin K, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg 2005;241:168-178.
54. Lang S, Tiwari S, Andratschke M, et al. Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. Cancer Immunol Immunother 2007;56:1645-1652.